An observational study in Hemophilia, sponsored by AstraZeneca. Completed at 2 sites in Sweden. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-02.
Sponsored by AstraZeneca · Observational
The purpose of this study is to collect reference data in patients with haemophilia. The study will also collect and store blood samples for potential future exploratory research in the disease area.
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
This study's planned enrollment of 50 is below the median of 80 across 314 observational studies indexed under Hemophilia A.
Browse Hemophilia A studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with haemophilia
Exclusion Criteria:
Laboratory variables
Other: Laboratory variables
1 visit
Laboratory variables related to coagulation, SAEs in connection to blood sampling procedures will be collected, non-serious AEs will not be recorded
Time frame: The variables will be measured at first visit.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca